NF-κB as potential target in the treatment of melanoma

Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

(2011) Paul B. Chapman et al.   NEW ENGLAND JOURNAL OF MEDICINE

A study of paclitaxel, carboplatin, and bortezomib in the treatment of metastatic malignant melanoma

(2010) Gary A. Croghan et al.   CANCER

Melanoma: A model for testing new agents in combination therapies

(2010) Paolo A Ascierto et al.   Journal of Translational Medicine

Enhanced anti-tumor activity of a new curcumin-related compound against melanoma and neuroblastoma cells

(2010) Marina Pisano et al.   Molecular Cancer

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Curcumin and Gemcitabine in Patients With Advanced Pancreatic Cancer

(2010) Ron Epelbaum et al.   NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL

A Phase I Trial of Bortezomib with Temozolomide in Patients with Advanced Melanoma: Toxicities, Antitumor Effects, and Modulation of Therapeutic Targets

(2009) Y. Su et al.   CLINICAL CANCER RESEARCH

Results of a Phase III, Randomized, Placebo-Controlled Study of Sorafenib in Combination With Carboplatin and Paclitaxel As Second-Line Treatment in Patients With Unresectable Stage III or Stage IV Melanoma

(2009) Axel Hauschild et al.   JOURNAL OF CLINICAL ONCOLOGY

Modulation of anti-apoptotic and survival pathways by curcumin as a strategy to induce apoptosis in cancer cells

(2008) Simone Reuter et al.   BIOCHEMICAL PHARMACOLOGY

NEMO-binding domain peptide inhibits proliferation of human melanoma cells

(2008) Angela Ianaro et al.   CANCER LETTERS

Double-Blind Randomized Phase II Study of the Combination of Sorafenib and Dacarbazine in Patients With Advanced Melanoma: A Report From the 11715 Study Group

(2008) David F. McDermott et al.   JOURNAL OF CLINICAL ONCOLOGY

Meta-Analysis of Phase II Cooperative Group Trials in Metastatic Stage IV Melanoma to Determine Progression-Free and Overall Survival Benchmarks for Future Phase II Trials

(2008) Edward L. Korn et al.   JOURNAL OF CLINICAL ONCOLOGY